Online inquiry

IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1125MR)

This product GTTS-WQ1125MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1125MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9710MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ6502MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ9325MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ4463MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ1314MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ7601MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ13362MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ4303MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW